id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-N-0258-0016,FDA,FDA-2020-N-0258,PRIA Reference 7 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T16:58:39Z,,0,0,090000648552f2ed
FDA-2020-N-0258-0020,FDA,FDA-2020-N-0258,PRIA Reference 11 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:47:36Z,,0,0,090000648552f2f1
FDA-2020-N-0258-0028,FDA,FDA-2020-N-0258,PRIA Reference 19 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:59:48Z,,0,0,090000648552f2fa
FDA-2020-N-0258-0002,FDA,FDA-2020-N-0258,Reference 1 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T15:09:16Z,,0,0,090000648552f118
FDA-2020-N-0258-0009,FDA,FDA-2020-N-0258,Reference 8 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T15:09:44Z,,0,0,090000648552f11f
FDA-2020-N-0258-0012,FDA,FDA-2020-N-0258,PRIA Reference 3 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T16:53:57Z,,0,0,090000648552f2e9
FDA-2020-N-0258-0015,FDA,FDA-2020-N-0258,PRIA Reference 6 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T16:57:41Z,,0,0,090000648552f2ec
FDA-2020-N-0258-0019,FDA,FDA-2020-N-0258,PRIA Reference 10 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:50:53Z,,0,0,090000648552f2f0
FDA-2020-N-0258-0021,FDA,FDA-2020-N-0258,PRIA Reference 12 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:49:09Z,,0,0,090000648552f2f2
FDA-2020-N-0258-0005,FDA,FDA-2020-N-0258,Reference 4 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T15:09:28Z,,0,0,090000648552f11b
FDA-2020-N-0258-0006,FDA,FDA-2020-N-0258,Reference 5 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T15:09:33Z,,0,0,090000648552f11c
FDA-2020-N-0258-0014,FDA,FDA-2020-N-0258,PRIA Reference 5 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T16:56:20Z,,0,0,090000648552f2eb
FDA-2020-N-0258-0018,FDA,FDA-2020-N-0258,PRIA Reference 9 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:06:20Z,,0,0,090000648552f2ef
FDA-2020-N-0258-0027,FDA,FDA-2020-N-0258,PRIA Reference 18 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:58:37Z,,0,0,090000648552f2f9
FDA-2020-N-0258-0004,FDA,FDA-2020-N-0258,Reference 3 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T15:09:24Z,,0,0,090000648552f11a
FDA-2020-N-0258-0007,FDA,FDA-2020-N-0258,Reference 6 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T15:09:37Z,,0,0,090000648552f11d
FDA-2020-N-0258-0022,FDA,FDA-2020-N-0258,PRIA Reference 13 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:51:58Z,,0,0,090000648552f2f4
FDA-2020-N-0258-0024,FDA,FDA-2020-N-0258,PRIA Reference 15 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:55:29Z,,0,0,090000648552f2f6
FDA-2020-N-0258-0026,FDA,FDA-2020-N-0258,PRIA Reference 17 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:57:35Z,,0,0,090000648552f2f8
FDA-2020-N-0258-0010,FDA,FDA-2020-N-0258,PRIA Reference 1 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T16:51:51Z,,0,0,090000648552f2dc
FDA-2020-N-0258-0017,FDA,FDA-2020-N-0258,PRIA Reference 8 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:04:04Z,,0,0,090000648552f2ee
FDA-2020-N-0258-0023,FDA,FDA-2020-N-0258,PRIA Reference 14 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:53:57Z,,0,0,090000648552f2f5
FDA-2020-N-0258-0003,FDA,FDA-2020-N-0258,Reference 2 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T15:09:20Z,,0,0,090000648552f119
FDA-2020-N-0258-0011,FDA,FDA-2020-N-0258,PRIA Reference 2 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T16:52:46Z,,0,0,090000648552f2dd
FDA-2020-N-0258-0013,FDA,FDA-2020-N-0258,PRIA Reference 4 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T16:55:08Z,,0,0,090000648552f2ea
FDA-2020-N-0258-0025,FDA,FDA-2020-N-0258,PRIA Reference 16 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T17:56:25Z,,0,0,090000648552f2f7
FDA-2020-N-0258-0029,FDA,FDA-2020-N-0258,PRIA Reference 20 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T18:00:44Z,,0,0,090000648552f2fb
FDA-2020-N-0258-0008,FDA,FDA-2020-N-0258,Reference 7 re: Investigational New Drug Application Annual Reporting,Supporting & Related Material,Background Material,2022-12-12T05:00:00Z,2022,12,,,2022-12-12T15:09:41Z,,0,0,090000648552f11e
FDA-2020-N-0258-0001,FDA,FDA-2020-N-0258,Investigational New Drug Application Annual Reporting,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2022-12-09T05:00:00Z,2022,12,2022-12-09T05:00:00Z,2023-03-10T04:59:59Z,2023-03-31T01:01:11Z,2022-26731,0,0,090000648552a78a